HLA-A Genotype

Many genetic tests ask whether one variant changes one pathway. This one tells you which two versions of an immune display gene you inherited. Those versions help decide which protein fragments from inside your cells get shown to your immune system, and that choice can matter for transplant compatibility, selected drug reactions, and a narrower set of infection, cancer, and autoimmune risk questions.

You inherit one copy from each parent, and the result does not change. Sequencing it once gives you an answer you can use for the rest of your life, in situations you may not be able to predict: a kidney donor offer, a long vancomycin course in a hospital, or a clinical trial that only enrolls people with a specific allele. No professional body recommends routine HLA typing for healthy adults, so the case for testing early rests on how likely one of those situations is to come up for you.

What the Test Actually Reads

HLA-A stands for human leukocyte antigen A. The gene sits in the major histocompatibility complex on chromosome 6, one of the most variable stretches of the human genome. It codes for a class I immune-display protein that pairs with beta-2 microglobulin and shows short protein fragments on the surface of nearly every cell with a nucleus.

Killer T cells read those fragments. A fragment from a virus or a mutated tumor protein can trigger a kill signal. A normal fragment usually does not. Which fragments your particular HLA-A versions can physically hold helps determine what your immune system can notice.

Modern high-resolution assays can read the full HLA-A gene, including coding and noncoding stretches. Older methods often focused on the coding stretches that form the groove where the protein fragment sits. That was enough for some broad matching questions. It was not enough for the finer ones.

Why the Old Methods Missed Things

Serologic typing and many sequence-specific or probe-based methods collapse the result into broad antigen groups. They may return a result like "HLA-A02" without telling you which A02 allele you actually carry. They can also leave a phasing problem: the lab sees two variants but cannot always tell which one came from which parent.

Full-length sequencing can reduce both problems. In a blinded audit of 10,063 registry donors typed from buccal swabs, sequencing across five HLA loci, including HLA-A, reached 99.84% accuracy. It also found rare alleles, novel exon sequences, and non-expressed null variants that older methods could have treated as ordinary matches. A separate validated clinical HLA sequencing assay reported 99.8% accuracy across 211 samples, with fully reproducible results on repeat testing.

The transplant consequence shows up when the whole HLA panel is retyped, not from HLA-A alone. When 103 living-donor kidney pairs were retyped at two-field resolution, 64.1% of pairs had mismatches that lower-resolution typing had missed. In a separate review of 385 solid organ transplant cases, high-resolution typing was judged instructive or necessary in 41%.

Transplant Matching

This is the oldest and strongest use of HLA typing. A mismatched HLA molecule on a donated organ or donated stem cells can look foreign to the recipient's T cells, which is how rejection and graft-versus-host disease begin. The finer the match, the fewer targets you hand the immune system.

Hidden mismatches matter because they can drive the recipient to build donor-specific antibodies. In the kidney study above, the newly uncovered mismatches were tied to higher mismatch burden in people with biopsy-proven antibody-mediated rejection. The signal came from extended HLA typing across multiple loci, not from HLA-A by itself.

The picture is not uniform across organs. In 92 liver transplant recipients, allele-level HLA mismatches were not independent predictors of acute rejection after adjustment for clinical factors. But the liver evidence runs both ways: in a larger living-donor liver transplant cohort, more mismatches at every locus tracked with worse recipient survival, and in more than a thousand recipients, greater difference between the donor's two class I molecules independently predicted acute and chronic rejection. Whether HLA matching changes liver transplant outcomes is still debated.

Severe Drug Reactions

Certain HLA-A alleles make a small set of drugs riskier. This is the context where knowing your genotype before you need it can be useful fast, though allergy guidelines support targeted testing tied to a specific drug decision rather than broad screening of everyone.

HLA-A*32:01 identifies people at elevated risk for DRESS during vancomycin treatment. DRESS is a delayed drug hypersensitivity reaction that can cause rash, fever, high eosinophil counts, liver injury, kidney injury, or other organ involvement. In the study that established the link, 82.6% of people with vancomycin-associated DRESS carried the allele, compared with none of the vancomycin-tolerant controls. A rapid allele-specific assay was developed so this allele can be checked before or during vancomycin therapy, especially when a long course is likely.

In a case-control study of 937 people in Japan, HLA-A*02:06:01 emerged as the primary susceptibility allele for Stevens-Johnson syndrome with severe eye complications triggered by over-the-counter cold medicines, carrying about five and a half times the odds of the condition. Stevens-Johnson syndrome is a reaction in which the skin and mucous membranes blister and peel. The ocular form can permanently damage vision.

For high-confidence drug-reaction alleles, the action is more concrete than it is for most disease-risk associations: record the result, and avoid or substitute the linked drug when a reasonable alternative exists. The genotype is permanent. The risk estimate may depend on ancestry, the exact drug, and the clinical setting.

Cancer Risk and Treatment Response

Because HLA-A helps decide which tumor-derived fragments get displayed, your genotype can shape how visible a cancer is to your own T cells. The effects are real but usually modest, and they point in different directions depending on the cancer.

In a UK Biobank analysis using SNP-imputed HLA types, 47,550 people who had already had one cancer were followed for a median of 3.11 years. Men carrying HLA-A*26:01 had about 27% higher risk of developing a second, unrelated primary cancer after adjustment for age, ethnicity, assessment center, and deprivation. The signal was concentrated in people whose first cancer was in the skin and whose second was in the lung.

In 226 people with surgically resected pancreatic cancer, an HLA class I pattern that included HLA-A02 along with B62 positivity and B44 absence predicted shorter disease-free survival, with a median of 239 days versus 410 days. This was not an HLA-A-only result. A standalone HLA-A test can tell you whether you carry A02, but it cannot tell you whether you carry the full risk pattern.

In head and neck squamous cell carcinoma, carrying HLA-A02 tracked with better survival in a small cohort. And in an epidemiological study pooling several cancer cohorts, with replication in randomized kidney cancer trials, HLA-A03 predicted poorer response to immune checkpoint blockade, with the strongest signal in people who carried two copies. These cancer drugs release the brakes on T cells.

Why the Same Gene Can Point in Opposite Directions

HLA-A is not a good-allele or bad-allele marker. It is a specificity marker. It determines which protein fragments your T cells can see, and different tumors produce different fragments.

An allele that displays a head and neck tumor's mutated proteins well may give your immune system a target. A different cancer may make fragments that the same allele displays poorly. Or the finding may depend on other HLA genes carried with it, as in the pancreatic cancer study. The lens matters, but so does what is in front of it.

This is why a single HLA-A result is not a cancer risk score. It is one input, and its meaning is specific to the disease and treatment being asked about.

Infection Severity

Your ability to present viral and bacterial fragments to T cells is partly inherited. The data here come mostly from meta-analyses, which pool studies of varying quality and often mix lower-resolution HLA groups with more precise allele calls.

A meta-analysis of 13 case-control studies covering 4,060 people found the broad HLA-A32 group associated with about 67% higher odds of tuberculosis, while the broad HLA-A1 group was associated with roughly 30% lower odds. Because many included studies used older HLA typing, these are not always exact high-resolution allele results.

A separate review of 19 studies and 10,551 people found several HLA-A groups or alleles, including A01, A03, A11, A23, A31, and A68, linked to severe COVID-19 or death. The individual studies adjusted for confounders inconsistently, so the result is a signal to interpret cautiously, not a clinical prediction rule.

The most carefully controlled infection finding comes from trauma. In 1,184 White critically injured adults on mechanical ventilation, carrying HLA-A*02:01 was tied to about half the odds of developing septic shock, and the effect held after adjustment for injury severity and clinical confounders. A specific amino acid change in the peptide-binding groove, 156Q, raised the odds of post-traumatic sepsis by about half.

Autoimmune Conditions

HLA associations with autoimmune disease are among the strongest in human genetics, but many of the famous ones live in class II genes such as DR and DQ, not in HLA-A. Sequencing HLA-A adds a layer. It does not replace the class II story.

In type 1 diabetes, clinical genetic risk screening has historically leaned on DR-DQ markers. Sequencing studies show that class I alleles can shift risk and age at onset: A24:02:01 was predisposing in a Chinese cohort, while A11:01:01 tracked with later onset.

In generalized vitiligo, HLA-A*02:01 is the main European risk allele tagged by the HLA-A signal, and the mechanism is unusually clear. The allele presents tyrosinase fragments to T cells. Tyrosinase is an enzyme involved in making pigment, so the immune target is built into the disease.

In a Spanish cohort of 49 people with acquired hemophilia A, HLA-A*03:01 was protective against the condition. The counterexamples are worth knowing too. In 91 people evaluated for aplastic anemia, class II alleles carried the stronger signal while no HLA-A allele drove the result. In a Kuwaiti ALS study, the risk signal also traced to a class II haplotype rather than HLA-A.

When the Result Can Mislead You

The most common error is assuming a negative HLA-A result rules something out. It does not. It says nothing about HLA-B, HLA-C, or class II genes unless those were tested too.

• Gene coverage: a result from this gene only answers questions about this gene. Celiac risk, many type 1 diabetes risk models, and most transplant decisions need class II typing too.
• Resolution matters: a broad result like "A2" collapses many distinct alleles together. It is not interchangeable with a two-field or higher-resolution sequencing result.
• Linkage disequilibrium: HLA genes are inherited in blocks, so an apparent HLA-A association can really be a nearby class II allele traveling on the same haplotype.
• Ancestry-specific allele frequencies: an allele that is common in one population may be rare in another, and many risk estimates come from cohorts with limited ancestral diversity.
• Imputation is not sequencing: an array-based or direct-to-consumer report often predicts HLA type from nearby markers. That can be useful for research, but the error rate is high enough that it should not guide transplant or drug-safety decisions.
• Novel or rare allele calls: a rare allele can be real, but its clinical meaning may be uncertain if it has not been studied in the disease or drug context you care about.
• Tumor sequencing is different: a tumor can lose or silence one inherited HLA copy. That is a cancer feature, not a change in the genotype you were born with.
• Clinical-grade testing: transplant and drug-safety decisions should use a validated HLA typing method from a clinical lab, not a recreational genetics estimate.

One Test, For Life

Your genotype was fixed at conception. There is no trend to track, no retest interval, no response to intervention. Unlike almost every other test in a health panel, the value here comes from having the result ready when a decision appears.

The only reason to repeat it is technical. If a result comes from imputation, an older low-resolution method, or a report that does not name the alleles precisely enough for the decision at hand, confirm it with high-resolution typing. A transplant program may also require typing from its own accredited lab.

What does need ongoing attention is whatever your genotype flags. If you carry an allele tied to a drug reaction, that result belongs on your permanent medication alert list. If you carry an allele linked to earlier-onset type 1 diabetes and have a strong family history, the relevant follow-up is autoantibody and glucose monitoring, not repeat genotyping.

What To Do With an Unexpected Result

Start by matching the finding to a decision it actually touches. Most HLA-A alleles carry modest risk associations that change nothing about how you live. A few change something concrete.

If you carry a drug-hypersensitivity allele, put it in your medical record and in your phone. Tell any prescriber before an antibiotic decision gets made in a hurry. This is the highest-yield action the test produces.

If you are heading toward transplant, the HLA-A result is one piece of a panel. The full workup includes HLA-B, HLA-C, and the class II genes, plus anti-HLA antibody screening to detect existing sensitization from prior pregnancies, transfusions, or grafts. A transplant immunologist or the program's histocompatibility lab interprets these together.

If the result is being used alongside an autoimmune diagnosis or a strong family history of one, the useful next step is the disease-specific workup rather than more HLA-A testing: autoantibody panels, the relevant class II typing, and specialist input when the diagnosis or treatment plan depends on it. If a result comes back as a novel allele or as having uncertain meaning, a genetic counselor can help decide whether it should change anything.